Galapagos (NASDAQ:GLPG - Get Free Report) is projected to release its earnings data after the market closes on Friday, February 28th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $72.80 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.
Galapagos Trading Up 0.0 %
Shares of GLPG stock traded up $0.01 on Friday, hitting $26.74. The company had a trading volume of 286,483 shares, compared to its average volume of 328,102. The stock's 50-day moving average is $25.42 and its two-hundred day moving average is $27.04. Galapagos has a twelve month low of $22.36 and a twelve month high of $39.91.
Wall Street Analyst Weigh In
Several research firms recently issued reports on GLPG. Barclays restated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. Kepler Capital Markets lowered shares of Galapagos from a "hold" rating to a "reduce" rating in a research note on Wednesday, November 20th. TD Cowen cut Galapagos from a "strong-buy" rating to a "strong sell" rating in a research report on Thursday, January 9th. Royal Bank of Canada decreased their price objective on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a research note on Friday, November 1st. Finally, Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and lowered their target price for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. Five investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $26.75.
Read Our Latest Stock Analysis on GLPG
Galapagos Company Profile
(
Get Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Read More
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Strong Sell" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
